


PHARMACEUTICAL 2017



Arbutus Biopharma Corp Rank 211 of 292







PHARMACEUTICAL 2017



Arbutus Biopharma Corp Rank 211 of 292

The relative strengths and weaknesses of Arbutus Biopharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arbutus Biopharma Corp compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 130% points. The greatest weakness of Arbutus Biopharma Corp is the variable Other Expenses, reducing the Economic Capital Ratio by 143% points.

The company's Economic Capital Ratio, given in the ranking table, is -20%, being 23% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	132,564
Cost of Goods Sold	0
Intangible Assets	123,809
Liabilities, Current	10,585
Liabilities, Non-Current	0
Other Assets	12,601
Other Compr. Net Income	0
Other Expenses	287,437
Other Liabilities	62,329
Other Net Income	2,473
Other Revenues	1,491
Property and Equipment	6,945
Research and Development	61,253
Selling, General and Administrative Expense	39,438

Output Variable	Value in 1000 USD
Assets	275,919
Liabilities	72,914
Expenses	388,128
Revenues	1,491
Stockholders Equity	203,005
Net Income	-384,164
Comprehensive Net Income	-384,164
Economic Capital Ratio	-20%

